Ongoing decline · week 12
Beam Therapeutics adds 0.9% as money flow turns positive after 12 weeks
Our view last week
Last week's rebound found no follow-through: Beam Therapeutics stock slips 2.7% and sellers are back with 67% of the volume, after buyers held 81% seven days earlier. Price action shows an indecisive weekly candle, and the technical analysis reads a decline losing conviction, with ADX falling for 3 weeks and money flow less negative. The short on the sell signal stays 11.8% in profit.
This week's summary
After 12 weeks below zero, money flow on Beam Therapeutics has edged back into positive territory, while the stock closed up 0.9% on contracting volumes. The weekly technical analysis reads a decline that keeps losing conviction: ADX has fallen for 4 weeks and the MACD is still below its Signal line. Beam Therapeutics stock remains under its 20-day moving average, which capped the price action again this week. The short on the Sell signal is 11% in profit.
IQS Phase
55
ordinary
Signal Strength
5
decline losing steam
Sizing
MINIMUM
Ranking
#144 / 175
US stocks
Trade P&L %
+11.01%
from signal to date, no stop loss
Beam Therapeutics (BEAM) weekly chart — EMA50 · MACD · VWAP
Weekly chart · EMA50 · MACD · VWAP · Source: TradingView
Rank position
ranks 144th among the 175 sell signals for US stocks in our ranking, with a signal strength of 5 out of 100.
Sector context
SectorHealth Care
Benchmark ETFXLV
Sector regimein positive regime
Performanceweekly -2.65% · monthly -3.91%
BEAM belongs to the health care sector (reference ETF XLV). The sector is classified in positive regime according to our weekly reading.
restricted Platinum content